Onconetix, Inc. (NASDAQ:ONCO) Short Interest Down 85.4% in February

Onconetix, Inc. (NASDAQ:ONCO) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 193,900 shares, a drop of 85.4% from the January 31st total of 1,330,000 shares. Approximately 3.6% of the company’s shares are short sold. Based on an average trading volume of 8,480,000 shares, the short-interest ratio is currently 0.0 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC bought a new position in Onconetix in the fourth quarter worth $25,000. Geode Capital Management LLC purchased a new stake in shares of Onconetix in the 4th quarter worth about $35,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Onconetix by 83.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 562,691 shares of the company’s stock worth $2,926,000 after acquiring an additional 256,612 shares in the last quarter. Hedge funds and other institutional investors own 23.89% of the company’s stock.

Onconetix Stock Performance

Shares of NASDAQ:ONCO traded down $0.01 during midday trading on Thursday, hitting $0.31. 582,503 shares of the stock traded hands, compared to its average volume of 6,935,504. Onconetix has a one year low of $0.30 and a one year high of $21.40. The business’s 50 day moving average is $0.53 and its two-hundred day moving average is $2.54.

Onconetix (NASDAQ:ONCO) last announced its quarterly earnings results on Monday, December 9th. The company reported ($2.24) earnings per share (EPS) for the quarter.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.